Cobra Biomanufacturing and Kahr Medical have announced a partnership agreement to advance Kahr's Trans Signal Converter Protein (TSCP) technology using Cobra's Maxxpress service.
Cobra will develop and manufacture bulk quantities of Kahr's TSCP proteins for preclinical and future clinical testing.
Currently, two recombinant proteins, Kahr-101 and Kahr-102 are being tested in preclinical studies as potential treatments for rheumatoid arthritis (RA) and psoriasis.
Cobra has already developed a purification process for Kahr-101 and batches have already been produced for preclinical testing.
'Cobra's Maxxpress service and recombinant protein expertise can provide the required tools and solutions for companies looking to start on the road to clinical trials and market supply,' said Simon Saxby, chief executive of Cobra Biomanufacturing.
